Biopharma NewsBy
Trial Registered

Hansoh registers Phase 1 obesity trial for injectable HS-20136-2

The single- and multiple-dose study in healthy and obese adults joins a GLP-1-dominated obesity field where Hansoh's own mechanism is not yet disclosed.

Jiangsu Hansoh Pharmaceutical registered a Phase 1 trial testing single and multiple subcutaneous doses of HS-20136-2 in healthy and obese adults, with a primary completion date of May 14, 2027.
By AppliedXLTrial NCT07716241

Executive Summary

  • Jiangsu Hansoh Pharmaceutical has registered a Phase 1 study of its injectable candidate HS-20136-2, testing single and multiple ascending doses in healthy and obese adults ahead of a planned September 2026 start.
  • The trial's primary measure is adverse-event incidence, meaning the study is built to establish tolerability and dosing before any weight-loss signal is examined as a secondary measure.
  • The candidate enters an obesity field already carrying multiple Phase 3 and Phase 4 programs from Eli Lilly, Novo Nordisk, and other China-based sponsors, most built on GLP-1 receptor agonism, while HS-20136-2's own mechanism has not been established in the trial record.
  • Hansoh brings a completed track record in metabolic syndrome trials to a molecule with no prior human testing, placing this readout at the earliest point in the company's own development chain for the asset.

The new trial

Jiangsu Hansoh Pharmaceutical Co., Ltd. filed a new registry record for NCT07716241, a Phase 1 study evaluating single and multiple subcutaneous doses of HS-20136-2 in healthy and obese participants. The trial has not yet begun recruiting, with a planned start of September 22, 2026, and a primary completion date of May 14, 2027. It targets 92 participants across two arms under a randomized, quadruple-masked design. Eligibility separates participants into a single-ascending-dose cohort (BMI 19.0 to 28.0) and a multiple-ascending-dose cohort in participants with obesity (BMI 28.0 to 40.0). NCT07716241A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese ParticipantsNCT07716241

What the trial measures

The registered primary endpoint is the number of adverse events, including serious adverse events, tracked from the start of treatment through the end of study, roughly 57 days for the single-dose cohort and 112 days for the multiple-dose cohort. Secondary measures cover pharmacokinetic exposure (area under the plasma concentration-time curve), immunogenicity through anti-drug antibody testing, and body weight change from baseline. That structure marks this as a safety and dosing study: any weight-loss signal it produces is exploratory rather than the trial's decision-grade output. NCT07716241A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese ParticipantsNCT07716241

Where it sits competitively

Obesity drug development is dense and mechanistically convergent around GLP-1 receptor agonism. Among Chinese and multinational sponsors alone, Eli Lilly's tirzepatide and retatrutide, Novo Nordisk's semaglutide, and domestic entrants including Fujian Shengdi's ribupatide and Gan & Lee's bofanglutide are all already in Phase 3 or Phase 4 obesity or obesity-adjacent testing. HS-20136-2's target and mechanism class are not established in the trial record, so it cannot be placed on that GLP-1 axis with confidence; the comparison that can be made is modality and indication, where HS-20136-2 is an injectable entering a field where the leading candidates are also injectable peptides. No competitor in this trial's competitive field carries the same drug or an identical development stage, and there is no direct same-drug comparator on record.

Sponsor track record

Hansoh has completed 22 trials globally with none terminated, and the sponsor's broader pipeline spans 123 trials across every phase and status, including 26 not yet recruiting and 18 recruiting. Within metabolic syndrome specifically, Hansoh has run 2 trials, both completed, giving the sponsor operational experience running this indication class even though HS-20136-2 itself carries no prior human testing. There is no historical outcome record yet for HS-20136-2 in obesity, consistent with this being the molecule's first Phase 1 study.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.